Hamza Hashmi, Ambuj Kumar, Mohamed A Kharfan-Dabaja, Pashna N Munshi, Yoshihiro Inamoto, Zachariah M DeFilipp, Bhagirathbhai Dholaria, Tania Jain, Miguel-Angel Perales, Paul A Carpenter, Mehdi Hamadani, Binod Dhakal, Saad Z Usmani
Chimeric antigen receptor T-cell therapy (CAR-T) has revolutionized the management of relapsed and/or refractory multiple myeloma (RRMM). However, CAR-T treatment failure is not uncommon and remains a major therapeutic challenge. There is substantial variability across transplantation and cellular therapy programs in assessing and managing post CAR-T failures in RRMM. The American Society for Transplantation and Cellular Therapy (ASTCT) Committee on Practice Guidelines conducted an online cross-sectional survey between September 2023 and December 2023 to determine the myeloma, transplantation and cellular therapy physicians' practice patterns for surveillance, diagnosis, and management of CAR-T failure...
April 12, 2024: Transplantation and cellular therapy